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Abstract
Background: Aldosterone, one of the major culprits associated with the renin-angiotensin-aldosterone system
(RAAS), is significantly elevated following high salt administration in Dahl rats. Since we have previously
demonstrated that aldosterone (ALDO) upregulates cyclooxygenase (COX) expression in the kidney, the present
study was design to assess whether prostaglandin release is involved in the effects of chronic aldosterone
treatment on vascular function of the aorta from nonhypertensive Dahl salt-sensitive rats.
Findings: The effects of aldosterone on arachidonic acid metabolism and on the expression of cyclooxygenase
(COX)-2 were evaluated in the Dahl salt sensitive (DS) rat aorta, renal, femoral and carotid arteries. DS rats on a low
salt (0.3% NaCl) diet were treated with or without ALDO for four weeks. Indirect blood pressure (BP), the release of
prostacyclin (PGI2) and prostaglandin E2, and the expression of COX-2 were measured to assess the vascular
remodelling by aldosterone. Vascular function was also assessed by contractile responsiveness in the aorta to
phenylephrine. ALDO increased BP (17 ± 1%) and inhibited the basal release of PGE2. ALDO enhanced vascular
reactivity to phenylephrine and up regulated the expression of COX-2 in both aorta and renal vessels but reduced
COX-2 expression in the femoral artery.
Conclusions: These data reveal that the effect of ALDO in the vasculature is tissue specific and may involve the
inhibition of PGE2 release. Thus, suggesting a role for prostaglandins in the vasculopathic aspects of aldosterone.
Background
Salt-induced hypertension associated end-organ damage
may be due to direct effects of aldosterone on cardiac,
renal and other vascular tissues [1,2]. We previously
reported the salt content of the diet was crucial for the
hypertensive effect of aldosterone [3]. In fact, aldoster-
one produces a time-dependent increase in blood pres-
sure in the presence of a low-salt diet, but not in the
presence of a high-salt diet, implicating an inappropriate
control of plasma aldosterone levels during the develop-
ment of aldosterone-mediated hypertension. Also, we
have found that aldosterone-induced endothelial dys-
function in both normotensive and hypertensive rats
may be related to an involvement of the prostanoid
pathway. Others have shown that the effect of aldoster-
one in the vasculature was associated with an overpro-
duction of prostacyclin [4,5].
Prostacyclin (PGI2) and prostaglandin E2 (PGE2)h a v e
been found to be predominant products of cyclooxgen-
ase metabolism [6]. Reduced bioavailability, of one or all
of these protective endothelial factors, results in vascular
dysfunction, a condition that has been documented in
patients with hypertension, diabetes, atherosclerosis, and
angina [7-9]. Aldosterone modulates membrane recep-
tors and signalling molecules and influences the actions
of a variety of agents to sensitize the vasculature to
effects of various agents that induce vasoconstriction or
result in direct effects on growth and remodelling. How-
ever, the contribution of cyclooxgenase and its products
to the vascular effects of aldosterone on specific blood
vessels needs to be further examined. The renin-angio-
tensin-aldosterone system is involved in alterations of
vascular function in hypertensive patients, the study of
aldosterone effects on vascular function could be espe-
cially relevant in the hemodynamic abnormalities asso-
ciated with hypertension. Thus, the present study was
design to assess whether prostaglandin release is
involved in the effects of chronic aldosterone treatment
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Methods
Animals and diets
Male Dahl S (SS/Jr) rats (130-150 g, 4-5 weeks old,
twelve rats) were obtained from Charles River Labora-
tories, Wilmington, MA. All protocols involving animals
were previously approved by the Morehouse School of
Medicine Animal Care Committee. Guidelines followed
were those of the Public Health Service and the revised
animal welfare act as regulated by USDA. The rats were
housed in a room with 12 h light - dark cycles and,
after one week of acclimation, the rats were divided into
two groups (six rats/group) and food and water were
available ad lib. Group 1 was fed a low salt (LS; 0.3%
NaCl) and Group 2 was fed a LS with aldosterone
(ALDO;0.05 mg/kg/day) for three weeks. The systolic
blood pressure and body weight was measured prior to
start of diet and weekly thereafter. The salt diet was
obtained from Harlan Teklad, Madison, WI. Diets,
blood collection, and blood pressure measurements have
been previously described [10].
Vascular Preparation
T h er a t sw e r ee u t h a n i z e db yr a p i dd e c a p i t a t i o n ,i n
accordance with American Veterinary Medical Associa-
tion and the MSM Laboratory Animal Care Committee
guidelines. The thoracic aorta was rapidly but gently
removed to avoid stretching or damaging the endothe-
l i u ma n dw a sp l a c e di nc o l d( 4 ° C ) ,g a s s e d( 9 5 % O 2/5%
CO2), Krebs-Henseleit-bicarbonate solution (KHB)as
described previously[11]. The aorta was cleaned of all
adipose and connective tissue, and the midthoracic
region was cut into rings (3 mm long) for vascular reac-
tivity and prostanoid release experiments or kept intact
for western blot analysis.
For the vascular reactivity experiments, two adjacent
aortic rings were prepared from each animal and were
studied in a paired approach. The rings were mounted
on two 25-gauge stainless steel wires; one was attached
to a stationary stainless steel rod and micrometer and
the other was attached to a force displacement transdu-
cer (model FT-03D, Grass) for measurement of iso-
metric tension. The transducers were connected to
DataTrak recording and analysis program (Global Scien-
tific LLC) for a continuous record of contractile tension.
Immediately after being mounted, the aortas were
immersed in water-jacketed organ baths filled with 15.0
ml of KHB solution, maintained at 37°C, and continu-
ously gassed with 95% O2-5% CO2. The aortic rings
were gradually stretched (over a 30-min period) to an
optimal passive tension of 2.50 g [11,12] and then equi-
librated for 90 min. During the equilibration period, the
KHB solution in the organ baths was replaced with
fresh KHB solution every 20 min. The passive tension
was adjusted to maintain 2.50 g throughout the equili-
bration and experimental periods. After the equilibration
period, the aortic rings were stabilized by a single near-
maximal contraction phenylephrine (PE; 1 × 10
-6 M) to
avoid possible tachyphalaxis to PE during the subse-
quent cumulative concentration- response experiments.
After each contraction reached a stable plateau tension,
the endothelium-dependent vasodilator acetylcholine
was added to the baths (1 × 10
-7 M) to assess functional
integrity of the endothelium. The baths were rinsed
twice and the aortas were allowed to reequilibrate in
fresh KHB solution for 30-45 min before further experi-
mentation. The effects of aldosterone on vascular reac-
tivity to PE were examined by obtaining cumulative
concentration responses to PE (10
-9-10
-4 M) in endothe-
lium-intact aortas.
For the vascular prostanoid release experiments, the
aortic rings (3 mm long) were prepared from intact
thoracic aortas and were placed into chilled, gassed
KHB solution and allowed to stabilize for at least 30
min. The rings were then transferred into 12 × 75-mm
plastic culture tubes with 2 ml chilled KHB, and gradu-
ally warmed up to 37°C. After preincubation for 30 min
at 37°C, the KHB solution was carefully aspirated, and
then 1.0 ml of KHB was added to the tissues, gassed
continuously, and incubated for 45 min at 37°C. After
incubation, the KHB was collected and stored at - 80°C
until assayed for 6-keto-prostaglandin F1aalpha (stable
metabolite of prostacyclin) and prostaglandin E2 by
enzyme immunoassay (Cayman Chem. Corp., Ann
Arbor, MI) according to the manufacturer’s instructions.
Basal release reflected the steady- state release of the
prostanoids into the incubation medium (KHB) during
the 45-min incubation period and was normalized by
dry weight of aortic rings and expressed as picogram/
milligram dry tissue weight/45 min as described by Li
and Stallone [13].
Western Blot Analysis
Tissue samples of aorta, carotid and femoral were
homogenized in ice cold T-PER lysis buffer containing
protease inhibitor cocktail (Pierce, Rockford, IL). Homo-
genates were pellet at 3000 g for 5 minutes at 4°C and
supernatants were collected for Western blotting. Pro-
tein concentrations were determined by Bradford pro-
tein assay (Bio-Rad, Hercules, CA). To detect protein
levels of COX-2, tissue lysates (20 μg) were separated by
4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA) and elec-
tro-transferred onto polyvinylidene fluoride (PVDF)
membranes. The membranes were incubated overnight
at 4°C with specific antibodies to COX-2 (Santa Cruz
Biotechnology, Santa Cruz, CA). After incubation with
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detected using the enhanced chemiluminescence
method. Proteins levels from western blots were evalu-
ated by quantifying the band intensities using NIH
Image version 1.6.3 software.
Statistics
A mean ± SEM was calculated for each group. Statistical
significance (P < 0.05) was evaluated by the Mann Whit-
ney test (SigmaStat, SPSS, Inc., Chicago, IL).
Results
Treatment with ALDO increased systolic blood pressure
significantly from baseline to week 3 (Figure 1). The
greatest increase in blood pressure by ALDO occurred
at week 2 and 3. Body weight increased over time in
both groups but was not significantly different (data not
shown). To address the effect of aldosterone on vascular
remodeling, endothelium-derived factors (i.e. prostacy-
clin, PGE2) were measured as well as changes in the vas-
cular expression of COX-2. Basal release of prostacyclin
from the aortic rings was similar between the groups;
however, basal release of PGE2 was 62% higher in the
control when compared to the ALDO treated group
(Table 1). The expression of COX-2 protein was mea-
sured in various vessels from these animals to determine
if the aldosterone mediated upregulation of COX-2 was
tissue specific. In the control groups, COX-2 expression
was highest in the femoral arteries when compared to
the aorta, renal and carotid vessels (Figure 2). However,
chronic treatment with ALDO produced a significant
increase in COX-2 expression in the aorta and renal
vessels and reduced expression in the femoral artery.
Contractile response to phenylephrine was used to
assess the effect of ALDO on vascular function. ALDO
treatment increased the responsiveness of the aortic
rings to phenylephrine at concentrations 10
-9 -1 0
-4 M
(Figure 3).
Discussion
We sought to examine the impact of aldosterone on
vascular remodeling and function by assessing changes
in aortic contractility. The underlying molecular
mechanisms of aldosterone on prostaglandins were also
determined by measuring the expression of COX-2 and
the release of prostaglandins. Aldosterone was given in
the presence of low sodium diet to salt-sensitive rats. In
previous studies, we have shown that when these rats
are fed an enhanced sodium diet, angiotensin II and
aldosterone levels are increased and prostaglandin levels
are lowered [4]. Therefore, we hypothesized that activa-
tion of the mineralocorticoid receptor with aldosterone
contributes to the vascular remodeling and dysfunction
in salt-induced hypertensive rats and involves prosta-
glandin formation. The maj o rf i n d i n g so ft h i ss t u d y
reveal that ALDO-mediated enhancement of contractile
function in the rat aorta may be due in part to inhibi-
tion of PGE2 release. We also found that the response
to aldosterone was tissue specific.
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Figure 1 Effect of ALDO on Systolic Blood Pressure.I n d i r e c t
blood pressure was measured prior to start of experiment and
weekly thereafter in Dahl SS rats fed a low salt diet (0.3%) with or
without aldosterone. Values are means ± SEM, n = 6. #P ≤ 0.05, LS
vs. LS-ALDO.
Table 1 Status at week 3 of Dahl salt-sensitive male rats
fed a low salt (LS) diet with or without aldosterone
(ALDO)
Parameter LS LS-ALDO
Body Weight 322 ± 6 315 ± 5
Prostacyclin 1877 ± 165 1636 ± 92
Prostaglandin E2 300 ± 43 115 ± 14
a, b
Values are means SEM, n = 6;
aLS vs. LS-ALDO; prostacyclin vs. PGE2. Body
weight is expressed in grams and prostaglandin values are expressed as pg/
ml/mg ring wt.
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Figure 2 Effect of aldosterone on COX-2 expression is tissue
specific. Dahl salt-sensitive (SS) were fed a low salt (0.3%, LS) diet
with or without aldosterone (ALDO; LS-ALDO) diet for three weeks.
Values are means ± SEM, n = 6. #P ≤ 0.05, LS vs. LS-ALDO.
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and renal vessels, we suspect that the prostanoids are
highly involved in the vasculopathic effects of aldoster-
one. Several studies have demonstrated that aldosterone
stimulates an increase in the activity of various inflam-
matory agents, including COX-2-derived products, in
some experimental models of cardiovascular diseases
[3,5]. COX-2 stimulates renin release [14], which plays a
role in hypertension via the renin-angiotensin-aldoster-
one system. Excessive expression of COX-2 as observed
in this study may stimulate renin-angiotensin-aldoster-
one system and as suggested by others lead to increased
arterial pressure and vascular lesions in inflammatory
diseases, including hypertension and diabetes [15,8]. We
anticipated that an abundance of COX-2 would lead to
an increase in prostanoid release since COX mediates
the rate-limiting step in arachidonic acid metabolism.
However, we found in the aorta that prostacyclin levels
remained unchanged and PGE2 release was significantly
diminished during aldosterone treatment. Prostaglandin
levels are normalized by ring weight instead of protein
levels and this might account for the unexpected decline
in prostaglandin levels; however, others have used dry
tissue weight to normalize prostanoid findings [13].
Besides, we have found that plasma levels of prostaglan-
dins are also decreased by ALDO when COX-2 levels
are elevated (data not published). We suspect that
ALDO-mediated reduction in prostaglandin E2 release
may reflect a decrease in PGE2 synthase levels in the rat
aorta and thus lead to the decline in PGE2 production.
This decline in PGE2 might explain the enhanced
responsiveness to phenylephrine observed in this study.
Vascular function was assessed in the aorta following
chronic treatment with ALDO. The heighten respon-
siveness to phenylephrine in the aortas from the ALDO-
treated rats and the decrease in prostaglandin E2 release
suggested an involvement of the prostaglandins in the
contractile function mediated by aldosterone. Others
have shown that chronic treatment with aldosterone
impaired endothelial function in mesenteric resistance
arteries under normotensive and hypertensive conditions
by increasing COX-2-derived prostacyclin and throm-
boxane A2 [5]. However, in this study, COX-2-derived
prostacyclin was unchanged in the aorta. Although the
rat aorta is a large conduit vessel not involved in the
regulation of peripheral resistance, it has been well
established that the rat aorta is a relevant model for the
study of vascular function in vitro, the aorta’ss e n s i t i v i t y
to vasoconstrictor and vasodilator agonists is often
much lower than smaller resistance-level vessels; thus
this might offer some insight into the observed differ-
ences between these vessels. Besides, in this study,
COX-2 protein expression varied between blood vessels
by up regulating expression in the aorta and renal
arteries but down regulating expression in the femoral
arteries. ALDO may enhance contractile responses in
the rat aorta to phenylephrine by inhibiting the release
of PGE2 and in the mesenteric arteries by increasing
prostacyclin and thromboxane A2 release. In conclusion,
t h e s es t u d i e ss u g g e s tar o l ef o rp r o s t a g l a n d i n si nt h e
vasculopathic aspects of aldosterone.
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